Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
LENZ Therapeutics Inc. (NASDAQ : LENZ) Stock
MWN-AI** Summary
MWN-AI** Analysis
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Description
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.
Quote
| Last: | $5.3101 |
|---|---|
| Change Percent: | -4.49% |
| Open: | $5.54 |
| Close: | $5.3101 |
| High: | $5.58 |
| Low: | $5.225 |
| Volume: | 879,847 |
| Last Trade Date Time: | 07/13/2026 03:45:50 pm |
Stock Data
| Market Cap: | $427,420,977 |
|---|---|
| Float: | 29,130,961 |
| Insiders Ownership: | 0.22% |
| Institutions: | 43 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.graphitebio.com |
| Country: | US |
| City: | Solana Beach |
Recent News Releases
Subscribe to Our Newsletter
**MWN-AI FAQ is based on asking OpenAI questions about LENZ Therapeutics Inc. (NASDAQ: LENZ).
